MORGAN STANLEY PLC/PUT/ELI LILLY & CO/550/0.01/20.06.25 | Market Closed - Börse Stuttgart 20:04:05 28/06/2024 BST | ||
| 0.088 EUR | -1.12% |
|
| Current month | -36.69% | ||
| 1 month | -39.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 0.088 | -1.12% |
| 27/06/24 | 0.089 | -4.30% |
| 26/06/24 | 0.093 | +4.49% |
| 25/06/24 | 0.089 | -4.30% |
| 24/06/24 | 0.093 | -7.00% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:04 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | MB9P1W |
| ISIN | DE000MB9P1W3 |
| Date issued | 10/08/2023 |
| Strike | 550 $ |
| Maturity | 20/06/2025 (357 Days) |
| Parity | 100 : 1 |
| Emission price | 0.78 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.86 € |
|---|---|
| Lowest since issue | 0.087 € |
| Spread | 0.008 € |
| Spread % | 7.77% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
